Roche subcutaneous cancer immunotherapy granted MHRA approval
European Pharmaceutical Review
AUGUST 29, 2023
The Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised the first subcutaneous formulation of an anti-PD-(L)1 cancer immunotherapy to be made available to patients in Great Britain. The safety and efficacy profile was consistent with the IV formulation.
Let's personalize your content